Insights

Innovative Immunotherapy Platform Cour Pharmaceuticals utilizes a proprietary nanoparticle platform for antigen-specific immune tolerance, presenting opportunities to collaborate or supply specialized nanoparticle components or related research tools to advance autoimmune therapies.

Expanding Autoimmune Portfolio With ongoing development in multiple autoimmune conditions including PBC, T1D, MG, and celiac disease, there is potential to offer targeted diagnostic assays, biomarkers, or auxiliary therapeutic solutions to complement Cour's pipeline.

Strategic Collaborations Recent partnerships with pharmaceutical giants like Takeda, Ironwood, Roche, Pfizer, and Bristol Myers Squibb indicate a receptive environment for business development, especially in areas like immune modulation, drug delivery, and clinical trial support.

Funding & Growth Momentum Receiving $5 million in Series A funding backed by prominent investors suggests strong growth potential and readiness to expand manufacturing, research services, or clinical trial operations tailored to autoimmune therapies.

Leadership & Expansion Key executive appointments and recent news highlight Cour's commitment to strategic growth, signaling opportunities in executive advisory, specialized scientific services, and partnership development to accelerate their clinical-stage programs.

Similar companies to Cour Pharmaceuticals Development Co., Inc.

Cour Pharmaceuticals Development Co., Inc. Tech Stack

Cour Pharmaceuticals Development Co., Inc. uses 8 technology products and services including oEmbed, Google Cloud, JSON-LD, and more. Explore Cour Pharmaceuticals Development Co., Inc.'s tech stack below.

oEmbed
Dev Tools
Google Cloud
Infrastructure As A Service
JSON-LD
Javascript Frameworks
jQuery Migrate
Javascript Libraries
Moment.js
Javascript Libraries
Lodash
Javascript Libraries
Smartsheet
Project Management
Max Mega Menu
Widgets

Media & News

Cour Pharmaceuticals Development Co., Inc.'s Email Address Formats

Cour Pharmaceuticals Development Co., Inc. uses at least 1 format(s):

Cour Pharmaceuticals Development Co., Inc. Email Formats	Example	Percentage
FLast@courpharma.com	JDoe@courpharma.com	86%
LFirst@courpharma.com	DJohn@courpharma.com	11%
Last_First@courpharma.com	Doe_John@courpharma.com	1%
First.Last@courpharma.com	John.Doe@courpharma.com	2%

Frequently Asked Questions

What is Cour Pharmaceuticals Development Co., Inc.'s official website and social media links?

Cour Pharmaceuticals Development Co., Inc.'s official website is courpharma.com and has social profiles on LinkedIn.

What is Cour Pharmaceuticals Development Co., Inc.'s SIC code NAICS code?

Cour Pharmaceuticals Development Co., Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cour Pharmaceuticals Development Co., Inc. have currently?

As of December 2025, Cour Pharmaceuticals Development Co., Inc. has approximately 77 employees across 1 continents, including North America. Key team members include Chief People Officer: S. L.Chief Operating Officer: J. H.Associate Director Of Clinical Operations: B. R.. Explore Cour Pharmaceuticals Development Co., Inc.'s employee directory with LeadIQ.

What industry does Cour Pharmaceuticals Development Co., Inc. belong to?

Cour Pharmaceuticals Development Co., Inc. operates in the Biotechnology Research industry.

What technology does Cour Pharmaceuticals Development Co., Inc. use?

Cour Pharmaceuticals Development Co., Inc.'s tech stack includes oEmbedGoogle CloudJSON-LDjQuery MigrateMoment.jsLodashSmartsheetMax Mega Menu.

What is Cour Pharmaceuticals Development Co., Inc.'s email format?

Cour Pharmaceuticals Development Co., Inc.'s email format typically follows the pattern of FLast@courpharma.com. Find more Cour Pharmaceuticals Development Co., Inc. email formats with LeadIQ.

When was Cour Pharmaceuticals Development Co., Inc. founded?

Cour Pharmaceuticals Development Co., Inc. was founded in 2015.

Cour Pharmaceuticals Development Co., Inc.

Biotechnology ResearchIllinois, United States51-200 Employees

COUR is a clinical-stage biotechnology company working to reprogram the immune system to restore health in people suffering from autoimmune diseases. Using our proprietary COUR nanoparticle (CNP) platform for antigen-specific immune tolerance, we develop first-in-class disease-modifying therapies that target disease at its root—without suppressing normal immune system function. With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.

Company Overview

Website: courpharma.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2015
Employees: 51-200